Beijing Incuris Biological Products Research Institute

Beijing Incuris Biological Products Research Institute is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for solid tumors. The company leverages its proprietary Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) platforms to engineer immune cells capable of targeting specific tumor antigens. Its lead program is a GPC3-targeted CAR-T therapy currently undergoing Phase 1 clinical evaluation for the treatment of advanced hepatocellular carcinoma. Incuris focuses on optimizing cell persistence and infiltration within the tumor microenvironment to improve clinical outcomes in oncology. The institute operates advanced research and development facilities and maintains collaborations with leading clinical centers in China.